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Abstract
TNBC is an aggressive breast cancer subtype that does not express hormone receptors (estrogen and progesterone
receptors, ER and PR) or amplified human epidermal growth factor receptor type 2 (HER2), and there currently exist no
targeted therapies effective against it. Consequently, finding new molecular targets in triple negative breast cancer (TNBC)
is critical to improving patient outcomes. Previously, we have detected the expression of metabotropic glutamate receptor-
1 (gene: GRM1; protein: mGluR1) in TNBC and observed that targeting glutamatergic signaling inhibits TNBC growth both in
vitro and in vivo. In this study, we explored how mGluR1 contributes to TNBC progression, using the isogenic MCF10
progression series, which models breast carcinogenesis from nontransformed epithelium to malignant basal-like breast
cancer. We observed that mGluR1 is expressed in human breast cancer and that in MCF10A cells, which model
nontransformed mammary epithelium, but not in MCF10AT1 cells, which model atypical ductal hyperplasia, mGluR1
overexpression results in increased proliferation, anchorage-independent growth, and invasiveness. In contrast, mGluR1
knockdown results in a decrease in these activities in malignant MCF10CA1d cells. Similarly, pharmacologic inhibition of
glutamatergic signaling in MCF10CA1d cells results in a decrease in proliferation and anchorage-independent growth.
Finally, transduction of MCF10AT1 cells, which express c-Ha-ras, using a lentiviral construct expressing GRM1 results in
transformation to carcinoma in 90% of resultant xenografts. We conclude that mGluR1 cooperates with other factors in
hyperplastic mammary epithelium to contribute to TNBC progression and therefore propose that glutamatergic signaling
represents a promising new molecular target for TNBC therapy.
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Introduction
Despite advances in diagnosis and treatment over the last three
decades, breast cancer remains the second most common cause of
cancer death in women [1]. Approximately 15–20% of breast
cancers do not express hormone receptors (estrogen or progester-
one receptors, ER or PR) or amplify human epidermal growth
factor receptor 2 (HER2). Although it is heterogeneous [2], this
form of breast cancer, dubbed ‘‘triple negative breast cancer’’
(TNBC), shows considerable overlap with the ‘‘basal-like’’ subtype
[3–5] and tends to be the most aggressive form with the poorest
prognosis [6]. Because it is more likely to metastasize early and
recur rapidly after treatment [7], TNBC results in a dispropor-
tionate number of breast cancer deaths [6]. The therapeutic
challenge to clinicians is that TNBC does not respond to drugs
targeting hormone receptors or HER2, leaving cytotoxic chemo-
therapy as the only current option for systemic treatment [8]. That
is why finding new molecular targets will be essential to improving
outcomes in women with TNBC. In this study, we build on our
initial report [9] that glutamatergic signaling represents a potential
therapeutic target in TNBC in a preclinical model of TNBC
progression by presenting evidence suggesting that mGluR1 can
strongly contribute to malignant behavior and progression in
nontransformed mammary epithelium.
Metabotropic glutamate receptors (genes: GRM1-GRM8;
receptors: mGluR1-mGluR8) belong to a family of G-protein-
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coupled seven transmembrane domain receptors (GPCRs) [10]
that mediate responses to a diverse array of signaling molecules,
including hormones, neurotransmitters, chemokines, and auto-
crine and paracrine factors [11–14]. Pollock et al [15] first reported
a potential mechanistic link between glutamatergic signaling and
cancer after observing in a transgenic mouse model that
dysregulated mGluR1 activity results in melanoma formation
with high penetrance [15–17]. Consistent with these observations,
pharmacological inhibition of glutamatergic signaling blocks the
growth of melanoma cell lines and xenografts [16,18–20], and
mGluRs have been implicated as novel drivers of oncogenesis in
melanoma and other tumor types, with somatic mutations that
alter downstream mGluR1 intracellular localization signaling
having been recently reported [21,22].
Our earlier results suggested that glutamatergic signaling is a
potential therapeutic target in TNBC. For example, we reported
that inhibitors of glutamatergic signaling block TNBC cell
proliferation in a time- and dose-dependent manner correlating
with increased apoptosis in vitro [9]. These same compounds are
also effective against MDA-MB-231 xenografts in mice, which
express mGluR1 [9]. One of these inhibitors, riluzole, is a
glutamate release inhibitor in current clinical use that is FDA-
approved for amyotropic lateral sclerosis [23]. To explore how
mGluR1 might contribute to progression in TNBC and how
better we might target it, we evaluated mGluR1 function in a
progression series of isogenic triple negative cell lines derived from
MCF10A cells. The parental cell line (MCF10A) having been
originally isolated from a woman with fibrocystic change [24], the
members of the MCF10A series resemble the basal-like subtype
[25–27], express neither ER, PR, nor HER2, and recapitulate the
stages of breast carcinogenesis [28], making these cell lines a
reasonable in vitro model for TNBC progression [29,30]. In our
experiments, blocking glutamatergic signaling inhibited the growth
of the malignant members of the progression series, and mGluR1
expression contributed to malignant behavior in one of the benign
members of the series. Based on these data, we conclude that
mGluR1 can interact with other factors to promote progression in
hyperplastic mammary epithelium and therefore represents a
potentially promising therapeutic target in TNBC.
Materials and Methods
Ethics statement
All animal experiments were approved by the Wayne State
University Institutional Animal Care and Use Committee
(IACUC) and are encompassed by approved animal protocol
#A03-03-11. Veterinary care is provided 24 hours a day by one of
several vivariums located at Wayne State University. Vivariums
are regularly inspected by the U.S. Department of Agriculture
(USDA) Animal and Plant Health Inspection Service Animal
Care, and are accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International. The
animals were subjected to no unnecessary discomfort, pain, or
injury during these studies. In order to minimize the possibility of
pain and suffering, mice were euthanized when tumors reached a
volume of 1,600 mm3. Anesthesia and/or tranquilizing agents
(intraperitoneal ketamine and xylene) were used when indicated
and appropriate to minimize pain and discomfort. Harvesting of
tissue was performed only after the animals had been euthanized
by CO2 inhalation and cervical dislocation. Tissue microarrays
from breast cancer tissue were constructed under an exempt
protocol, specifically Exemption #4 (research involving the
collection or study of existing data, documents, records, patho-
logical specimens, or diagnostic specimens, if these sources are
publicly available or if the information is recorded by the
investigator in such a manner that subjects cannot be identified,
directly or through identifiers linked to the subjects) confirmed by
the UMNDJ-Robert Wood Johnson Medical School Institutional
Review Board. The tissue specimens used were pre-existing
samples that had been de-identified.
Cell Culture and reagents
The MCF10A series of cell lines were originally developed at
the Michigan Cancer Foundation (the institutional precursor to
the Karmanos Cancer Institute) and are available to us from
original stocks at low passage [28,31–33]. MCF10A series cell lines
were cultured in DMEM/F12 (1:1) media (Life Technologies,
Carlsbad, CA) supplemented with 5% horse serum, 10 mg/ml
insulin, 20 mg/ml EGF, 0.5 mg/ml hydrocortisone and 100 ng/ml
cholera toxin plus antibiotics at 37uC, 5% CO2. MCF10A and
MCF10AT1 transduced with pLenti-GRM1 or control LacZ were
grown with 5 to 8 mg/ml blasticidin (Life Technologies, Carlsbad,
CA); MCF10DCIS.com and MCF10CA1d transduced with
lentiviral GIPZ shGRM1 or non-silencing control were maintained
in 2 mg/ml puromycin (Life Technologies, Carlsbad, CA). The
noncompetitive mGluR1 inhibitor BAY36-7620 [(3aS,6aS)-6a-
naphtalen-2-ylmethyl-5-methyliden-hexahydro-cyclopental [c]-fu-
ran-1-on], competitive mGluR1 inhibitor LY367385 [(S)-(+)-a-
Amino-4-carboxy-2-methylbenzeneacetic acid], and mGluR1
agonist L-quisqualate [(L)-(+)-a-amino-3,5-dioxo-1,2,4-oxadiazoli-
dine-2-propanoic acid] were purchased from Tocris Bioscience
(Ellisville, MO, USA).
Constructs
GRM1 inserted in PCI-Neo vector was a kind gift from Suzie
Chen (Rutgers, The State University of New Jersey, Piscataway).
GRM1 was inserted into the pLenti6.3/V5-TOPOH cloning vector
(Life Technologies, Carlsbad, CA) to produce pLenti-GRM1, and
pLenti-LacZ was used as a control. To silence GRM1 expression,
we have previously validated five shRNA constructs targeting
human GRM1 from the Thermo Scientific Open Biosystems
Human GIPZ Lentiviral shRNAmir library (Lafayette, CO) for
their ability to knock down GRM1 expression prior to use [9].
Approximately 56105 TU/ml of either pLenti6.3/V5-TOPOH
GRM1 or LacZ control were used to infect selected cell lines, which
then underwent selection using blasticidin, with measurements
performed on pooled samples of transduced cells. For overexpres-
sion, cells were used approximately 3 to 8 passages after infection
with expression vector. For silencing, cells were used 2 to 4
passages after infection. GRM1 and mGluR1 expression were
confirmed by QRT-PCR and Western blot, respectively according
to previously published methods [9]. To silence GRM1, the Trans-
Lentiviral GIPZ Packaging System (Thermo Scientific Open
Biosystems, Lafayette, CO) was used to generate viral particles
according to the manufacturer’s protocol. Approximately 56105
TU/ml of shGRM1 was used to infect cells, which then underwent
short term selection with puromycin, after which pooled cell
populations were used as with the overexpression experiments.
Non-silencing vector was used as a control. Knockdown was
verified by qRT-PCR and Western blot.
Human tumor samples
We obtained 49 breast cancer and 10 normal breast specimens
from reduction mammoplasties under an IRB-approved protocol
from the Tissue Retrieval Service (TRS), a shared resource of The
Cancer Institute of New Jersey. Tissue specimens were coded to
protect patient confidentiality according to HIPAA regulations.
The only clinical information that accompanied the specimens was
mGluR1 is a Molecular Target in Breast Cancer
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the level of progression (primary tumors versus nodal metastatic
tumors). Each sample was obtained at the time of resection and
either immediately flash-frozen and stored in liquid N2 or fixed in
buffered formalin.
RT-PCR analysis of GRM1 expression
Total RNA was extracted from tissue and cell lines using
RNeasy Plus Mini Kit (Qiagen, Valencia, CA) and subjected to
reverse transcription using High-capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems-Life Technologies, Carlsbad,
CA). QRT-PCR was performed using TaqMan universal qPCR
master mix (Applied Biosystems/Life Technologies, Carlsbad, CA)
and the following primers and probes:
GRM1
Sense 59-GCA?CGG?CCT?GCA?AAG?AGA?ATG?AAT-39
Antisense 59-TCC?ACT?CAA?GAT?AGC?GCA?CAG?
GAA-39
Probe 59-/56-FAM/TCA?CCT?GCA?AAG?CTT?GTG?
ACT?TGG?GA/3BHQ_1/-39
b-actin
Sense 59-TCA?GCA?AGC?AGG?AGT?ATG?ACG?AG -39
Antisense 59-ACA?TTG?TGA?ACT?TTG?GGG?GATG-39
Probe 59-/56-FAM/ACG?GTG?AAG?GTG?ACA?GCA?
GTG?G/3BHQ_1/-39
Thermal cycling was performed as follows: 10 min. denaturing
step at 95uC, followed by 40 cycles of denaturation consisting of
15 s at 95uC; annealing/extension at 60uC for 60 seconds.
Product sizes were 126 bp for GRM1 and 264 bp for b-actin.
Lack of contaminating genomic DNA was verified using no-RT
controls. Each sample was run in triplicate and Ct determined for
GRM1 and b-actin. The GRM1/b-actin ratio was estimated using
the DDCt method as described [34,35].
Immunoblotting
Protein lysates were collected by scraping cells in RIPA lysis
buffer (Santa Cruz, CA). Protein (30 to 100 mg) was separated by
SDS-polyacrylamide gel electrophoresis (4 to 20%) and transferred
to polyvinylidene fluoride membranes. Immunodetection of
mGluR1 (BD Pharmagen, San Jose, CA), and phosphorylated or
total ERK (Cell Signaling, Canton, MA), was performed using
primary antibodies to these antigens with appropriate secondary
antibodies followed by detection using chemiluminescence.
Primary blots were stripped and reprobed with antibody against
a-tubulin (Sigma-Aldrich, St. Louis, MO) or GAPDH (Novus
Biologicals, Littleton, CO).
Immunohistochemistry and CTMA4 breast tissue
microarray
Additional paraffin-embedded breast cancer specimens corre-
sponding to the frozen tissue samples used in the qRT-PCR
studies were obtained from the Tissue Retrieval Service. In
addition, a breast cancer tissue array (CTMA4) was constructed
and contained 580 cores representing approximately 145 cases (4
cores per case), consisting of 115 cases of invasive ductal
carcinoma, 15 cases of invasive lobular carcinoma, one case of
atypical hyperplasia, 12 cases of ductal carcinoma in situ and 2
cases of soft tissue metastasis. The array has been validated, with
each spot examined and confirmed to consist of at least 80%
cancer cells. 4 mm paraffin sections were cut and mounted on glass
slides, deparaffinized, and treated with Protease 1 at 37uC before
anti-mGluR1 was applied. Staining was detected using Ventana’s
prediluted HRP-tagged universal secondary antibody followed by
incubation in DAB using the DAB MAP kit (Ventana Medical
Systems). A breast cancer pathologist read the array in a blinded
fashion.
Cell proliferation and growth
Cells under the experimental conditions tested (described in the
text) were plated at a density of 16104 cells per well in 96-well
tissue culture plates (Corning Incorporated, Corning, NY). Cells
were transduced with Lentiviral vectors expressing either GRM1
or control, and the proliferation of the pooled cell populations was
determined using the Cell Titer Non-Radioactive Cell Prolifera-
tion Assay (MTT Assay) according to manufacturer’s protocol
(Promega, Madison, WI). In addition, cell growth was measured
by plating 56104 cells in 6-well tissue culture plates (Corning
Incorporated, Corning, NY), after which cells were trypsinized
and counted every day using a Coulter counter. (Beckman-
Coulter, Brea, CA). Similarly, cells were transduced with GIPZ
Lentiviral vectors expressing either shRNA against GRM1 or
scrambled control.
Migration/invasion assays
For migration and invasion assays, 2.56105 MCF-10 series cells
transduced with either pLenti-GRM1 or, pLenti-LacZ, or shGRM1
or control nonsilencing vector were plated on cell inserts with
polycarbonate membranes (0.8 mm pore size, BD Biosciences, San
Jose, CA).For invasion assays cell inserts were coated with Matrigel
(0.8 mm pore size, BD Biosciences, San Jose, CA). Cells were
allowed to invade the Matrigel or migrate towards serum (10%) as
the chemoattractant for 16 to 24 hours after which non-migrating
or non-invading cells were scraped off and the cells on the other
side of the membrane were stained by H&E and the migrated and
invaded cells were counted manually. For all experiments, to
exclude the possibility that the effect of migration or invasion may
be because of the differences in cell counting or the functional rate
of proliferation, we plated an MTT assay in parallel with
migration and invasion assays and confirmed that there were no
differences in seeding densities and cell proliferation during
incubated times between experimental groups.
Soft agar assay and live cell imaging
MCF-10 series cells either (1) stably transduced with either
GRM1 or control LacZ; (2) stably transduced with shGRM1 or
control nonsilencing vector; or (3) treated with BAY, were assayed
for anchorage-independent growth in a 0.4% agar solution in six
well plates. Selection media or BAY-supplemented media was fed
thrice a week for three weeks. After three weeks, colonies were
stained with p-iodonitrotetrazolium violet (Sigma-Aldrich, St.
Louis, MO) overnight, and counted on Gel Count machine
(Oxford Optronix, Oxford, UK). For 3D live cell cultures of
MCF10A series cells, 1.56103 cells were seeded on 12 mm
coverslips precoated with rBM (CultrexH, R & D Systems,
Minneapolis, MN) followed by the addition of a 2% rBM overlay
[29]. The morphology of cells and degree of colony formation in
the 3D rBM were assessed by visual examination of 16 contiguous
fields under differential interference contract (DIC) microscopy at
day 4 in culture as described [36]. All images were obtained using
a Zeiss LSM-510 META confocal microscope.
Xenografts
MCF10AT1 cells (16107), wild-type or stably transduced with
either pLenti-GRM1 or pLenti-LacZ, were suspended in 0.5 mL of
reconstituted basement membrane (BD Matrigel, BD Biosciences,
San Jose, CA) into both flanks of female athymic nude (nu/nu)
mice, aged 6 and 8 weeks (Taconic Farms Inc., Germantown,
mGluR1 is a Molecular Target in Breast Cancer
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Figure 1. GRM1 and mGluR1 expression and activity in breast cancer. A. GRM1message is expressed at significantly higher levels in
breast cancer versus normal breast. GRM1 message was measured by qRT-PCR in 49 human breast cancers and 10 normal breast specimens. The
whiskers in the box-and-whiskers plot represent a percentile range from 10 to 90. Cancer and control groups were compared using the unpaired t-
Mann-Whitney test with Welch’s correction (p = 0.0007, arbitrary units normalized to GAPDH 6 SEM). B. mGluR1 expression in human breast
cancer. Staining was patchy, with some breast cancer cells showing intense staining and others showing light staining, suggesting a mosaic of
mGluR1-positive and mGluR1-negative cells in this specimen (magnification: 1006). C. mGluR1 expression in normal breast tissue. Little to no staining
was observed in normal ductal and lobular epithelial cells. However, there was significant staining observed in the tissue vasculature, primarily the
epithelial cells. (Magnification 406) D. mGluR1 expression in a breast cancer tissue microarray. The CTMA4 breast cancer tissue array was
subjected to mGluR1 IHC as described in Materials and Methods and the TMA examined by a breast pathologist (N. B.).
doi:10.1371/journal.pone.0081126.g001
Figure 2. mGluR1 is active in a TNBC cell line. BT549 cells were stimulated in glutamate-free media containing GlutaMAXTM (Life Technologies,
Grand Island, NY) with mGluR1 agonist, L-quisqualate (10 mM). Cells were harvested and the fold-increase in phosphorylated ERK1/2 was assayed by
Western blot. Pretreatment with mGluR1 antagonist LY367385 for 30 minutes markedly reduced pERK1/2 induction by L-quisqualate (right side of
gel). Bottom gel: Same blot stripped and re-probed with ERK antibody for normalization. Experiments were repeated two times with similar results.
doi:10.1371/journal.pone.0081126.g002
mGluR1 is a Molecular Target in Breast Cancer
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NY). Mice were observed for lesion formation twice a week and
euthanized after eight weeks, when lesions were harvested at the
injection site, fixed in buffered formalin, and embedded in paraffin
for histological examination. Lesions were then examined micro-
scopically for foci of carcinoma.
Statistics and data analysis
All in vitro studies were repeated at least three times and, unless
otherwise noted, statistical significance was determined either by
one-way ANOVA, chi-square, or unpaired Student’s t-test, as
appropriate.
Results, Discussion, and Conclusions
mGluR1 expression and activity in breast cancer
To determine whether mGluR1 is expressed in human breast
cancer we measured GRM1 mRNA by qRT-PCR in 49 flash-
frozen human breast cancer specimens and 10 specimens of
normal breast taken from reduction mammoplasties. Significantly
higher GRM1 message was detected in the invasive cancers
(Figure 1A). mGluR1 protein expression was also detected by
immunohistochemistry (IHC) in primary cancers (Figure 1B) and
metastatic lesions (not shown). In carcinoma, mGluR1 expression
was patchy, with some breast cancer cells showing intense staining
and others showing minimal staining, suggesting a mosaic of high-
expressing and low-expressing cells. In contrast, in normal breast
tissue, virtually no staining could be seen in the actual breast
lobules and ducts, although the vasculature of the breast tissue did
demonstrate moderate to intense staining with anti-mGluR1
antibody (Figure 1C). IHC performed on the CTMA4 breast
cancer tissue array confirmed that mGluR1 expression is common
in breast cancer, with 60% of invasive ductal carcinomas and 47%
of invasive lobular cancers, but not benign lesions, expressing high
levels of mGluR1 (Figure 1D).
mGluR1 expression and activity in a high-expressing
TNBC cell line
Next, we tested the effect of modulating mGluR1 signaling in a
TNBC cell line (BT549) that was chosen because it endogenously
expresses a high level of mGluR1 and is more sensitive to
pharmacologic blockade of mGluR1 than other TNBC cell lines
we have tested thus far [9]. In addition, BT549 cells grow well in
glutamate-free medium supplemented with GlutaMAXTM (Life
Technologies Grand Island, NY). BT549 cells were stimulated
with the Group I mGluR agonist, L-quisqualate. This resulted in a
rapid increase in phosphorylation of mGluR1 downstream target
ERK1/2, an effect reduced by pre-incubation with the compet-
itive mGluR1 antagonist LY367385 (Figure 2). These results
suggest that mGluR1 is active in TNBC.
mGluR1 expression and activity in an isogenic breast
cancer progression series
To further explore mGluR1 activity in TNBC, in particular, in
the progression from normal epithelium to triple negative breast
cancer, we measured its expression in the MCF10 progression
series of cell lines, which serve as models for mammary epithelial
progression [27]. Originally based on observations that human
breast cancer cell lines contain mutationally activated ras
oncogenes, and many breast carcinomas express higher levels of
the ras proto-oncogene protein product than do normal tissues
[37,38], these cell lines were constructed to explore breast cancer
progression and include lines representing fibrocystic breast tissue
(MCF10A) [24], atypical hyperplasia (MCF10AT1, Ha-ras/HRAS
transformation of MCF10A) [31], ductal carcinoma in situ
(MCF10DCIS.com) [39,40], and invasive TNBC (MCF10CA1d)
[33,41]. Although HRAS is seldom mutated in breast cancer, it is
thought that elevated expression could result from upregulated
signaling pathways involving these GTPases due to increased
coupling to growth factor receptors or other tyrosine kinases
commonly overexpressed breast cancer, or increased expression of
regulators, the Ras protein itself, or downstream effectors [42],
and there is a precedent for cooperation between other genes and
HRAS in this series, for example BMI1 [43]. Consistent with a
possible role in TNBC progression, GRM1 mRNA and mGluR1
protein expression was low in MCF10A normal mammary
epithelial cells cells compared to premalignant MCF10AT1 cells
and malignant MCF10DCIS.com and MCF10CA1d (Figure 3,
A and B).
Next, we modulated mGluR1 expression in MCF10 series cell
lines using a Lentiviral expression vector (pLenti-GRM1) to
overexpress mGluR1 in the benign and premalignant members
of the MCF10A series (MCF10A and MCF10AT) and a Lentiviral
vector expressing shRNA to silence mGluR1 expression in the
malignant members of the series (MCF10DCIS.com and
Figure 3. Expression of GRM1 and mGluR1 in the MCF10 progression series. A. GRM1mRNA expression. RNA lysates collected from the
progression series cells were synthesized to cDNA and qRT-PCR analysis performed as described in Materials and Methods. Relative fold change GRM1
expression of MCF10AT1, MCF10DCIS.com, and MCF10CA1d are compared to MCF10A cells. B. mGluR1 protein expression. Protein lysates were
immunoprecipitated with mGluR1 antibody as described in Materials and Methods. Premalignant MCF10AT1 and malignant MCF10DCIS.com, and
MCF10CA1d express increased levels of GRM1 and mGluR1 compared to parental MCF10A cells, with MCF10DCIS.com expressing the highest levels.
doi:10.1371/journal.pone.0081126.g003
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MCF10CA1d) (20). We began with MCF10A cells, in which
vector-driven GRM1 and mGluR1 expression was confirmed
(Figure 4, A and B). We then tested the effect of overexpressing
mGluR1 in MCF10A cells and, disappointingly, observed no
significant effect on proliferation (Figure 4C), invasion through
Matrigel-coated polycarbonate membranes (Figure 4D), and
colony formation in soft agar (Figure 4E). Given this finding, we
asked whether mGluR1 might function later during TNBC
progression, as represented by MCF10AT1 cells, which represent
atypical ductal hyperplasia.
To address this issue, we studied the effect of modulating
mGluR1 expression and activity in MCF10AT1 cells (Figure 5, A
and B), as well as the ability of the GIPZ shRNA pLenti vector
silencing constructs to silence GRM1 in MCF10DCIS.com and
MCF10CA1d cells lines (Figure 5C) and in GRM1 overexpressed
MCF10AT1 (GRM1-MCF10AT1) cells (see Figure 5, D and E).
We then transduced MCF10AT1 cells with pLenti-GRM1 or
pLenti-LacZ. In contrast to the lack of effect in MCF10A cells
compared to the LacZ control as measured by MTT assay on day 3
(Figure 4C), there was a significant increase in proliferation in
GRM1-MCF10AT1 cells compared to the LacZ control as
measured by MTT assay (Figure 6A) and cell count
(Figure 6B) on day 3. Glutamatergic signaling was then inhibited
using BAY, resulting in a significant decrease in cell growth over
six days compared to controls (Figure 6C). To confirm our
results, we blocked GRM1 overexpression in the GRM1-
MCF10AT1 cells using shGRM1 and noted a modest but
significant decrease in cell number compared to the non-silencing
control (Figure 6D). A similar decrease in cell growth was also
observed in GRM1-MCF10CA1d cells silenced with shGRM1
Figure 4. Increasing mGluR1 activity has no effect on measures of oncogenesis in MCF10A cells. A. GRM1 expression. RNA lysates from
stable transfectants of GRM1-MCF10AT1 or control LACZ cells were isolated and subjected to qPCR as described in Materials/Subjects and Methods.
GRM1 is expressed at a level approximately 1.86104 times higher in GRM1-transduced MCF10A cells than in LacZ control infected cells. B. mGluR1
expression. Protein lysate (30 mg) was loaded in each lane. The membrane was stripped and reprobed for tubulin antibody to show equal loadings.
(LacZ=pLenti-LacZ; GRM1=pLenti-GRM1). C. Effect of mGluR1 overexpression on proliferation. Lentivirus-driven mGluR1 expression had no
effect on the proliferation of MCF10AT1 cells compared to the control as measured by MTT assay. For MTT assay, 16104 cells were plated and cell
proliferation was analyzed on day 3. D. Effect of mGluR1 expression on MCF10A migration. GRM1 overexpression in MCF10AT1 cells had no
effect on MCF10A migration compared to the control LacZ-transduced cells. E. Effect of mGluR1 expression on anchorage-independent
colony formation. MCF10A cells were transduced with either with pLenti-GRM1 or pLenti-LacZ and plated in soft agar as described in Materials and
Methods. GRM1 overexpression had no effect on the number of colonies on soft agar compared to the control LacZ cells. All experimenbts were
performed in triplicate and results are recorded as the mean 6 SEM of three experiments, where *p,0.05 compared to control.
doi:10.1371/journal.pone.0081126.g004
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compared to the non-silencing vector infected cells (Figure 6E).
These results suggest that excessive mGluR1 expression and
activity play a role in the proliferation of hyperplastic mammary
epithelium.
mGluR1 regulates migration and invasion of MCF10
series cells
Because the effects of inhibiting mGluR1 activity on prolifer-
ation were modest, we investigated whether glutamatergic
signaling is more important in promoting other oncogenic cell
functions. mGluR1 overexpression in MCF10AT1 cells resulted in
increased migration (Figure 7A), an effect reversed by silencing
mGluR1 with shGRM1 (Figure 7B). Consistent with this result,
invasion through reconstituted basement membrane increased
when mGluR1 was overexpressed in MCF10AT1 cells
(Figure 7C), but not in GRM1-overexpressing MCF10A (not
shown)). Finally, the invasiveness of malignant MCF10CA1d cells
decreased when mGluR1 was silenced with shGRM1 vector
(Figure 7D). Our results suggest that mGluR1 activity promotes
migration and invasion in premalignant and malignant TNBC
cells, but not in nontransformed epithelium.
Figure 5. mGluR1 expression and silencing. GRM1 overexpression results in mGluR1 protein overexpression in MCF10AT1 cells. A.
GRM1 expression. RNA lysates from stable transfectants of GRM1-MCF10AT1 or control LACZ cells were isolated and subjected to QPCR as described
in Materials/Subjects and Methods. GRM1 was expressed at a level 1.66105 times higher in stable transformed GRM1-MCF10AT1 cells than in LacZ
control infected cells. B. mGluR1 expression. Protein lysate (30 mg) was loaded in each lane. The membrane was stripped and reprobed for tubulin
antibody to show equal loadings. (LacZ=pLenti-LacZ; GRM1=pLenti-GRM1). C, D. GRM1 silencing. RNA lysates from MCF10DCIS.com and
MCF10CA1d cells with Lentivirus-driven expression of shGRM1 or NS vector were subjected to qPCR analysis. GRM1 expression was significantly
silenced by 0.5 and 0.25 fold in shGRM1 transduced MCF10DCIS.com and MCF10CA1d cells respectively, compared to the NS control infected cells (C).
GRM1-MCF10AT1 cells were silenced with either shGRM1 or NS control vector and GRM1 mRNA message was analyzed using QPCR. GRM1 is
significantly silenced by 0.48 fold in GRM1-MCF10AT1 cells compared to the NS control infected cells (D). E. mGluR1 silencing. Protein lysate
(50 mg) was loaded in each lane. mGluR1 is also silenced by shGRM1 in GRM1-MCF10AT1 cells compared to the NS control cells. qPCR was performed
in triplicate and results are recorded as the mean 6 SEM of three experiments, where *p,0.05 compared to control. (For C, D, and E: NS=pLenti
vector containing nonsilencing control: shGRM1=pLenti vector containing shRNA against GRM1.)
doi:10.1371/journal.pone.0081126.g005
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Glutamatergic signaling promotes anchorage-
independent growth in vitro
pLenti-GRM1 was used to drive mGluR1 expression in
MCF10AT1 cells suspended in soft agar and resulted in a 185%
increase in colony number compared to control (Figure 8A). We
then tested the specificity of this effect by silencing overexpressed
mGluR1 using shGRM1 and observed a 40% decrease in colony
formation compared to non-silencing control (Figure 8B). Next,
we silenced mGluR1 in MCF10CA1d cells and observed a 50%
decrease in colony formation (Figure 8C). Inhibition of
glutamatergic signaling using BAY in MCF10DCIS.com and
MCF10CA1d cells also resulted in a dose-dependent decrease in
colony formation (Figure 8, D and E). Finally, we cultured
GRM1-transduced MCF10AT1 cells in a 3D reconstituted
basement membrane overlay system (3D rBM) [29,44,45].
GRM1-transduced MCF10AT1 cells formed disorganized, inva-
sive structures with three times the diameter of LacZ-transduced
controls (Figure 8F). Our results suggest that mGluR1 plays a
significant role in promoting a more malignant phenotype in cells
(MCF10AT1) modeling ADH but not nontransformed mammary
epithelial cells (MCF10A)
mGluR1 contributes to the transformation of hyperplasic
MCF10AT1 cells
Finally, we tested whether overexpressing mGluR1 can
contribute to the transformation of MCF10AT1 cells. Xenografts
from this cell line form glandular structures with varying grades of
atypia in nude mice, with approximately 25% of xenografts
developing foci of carcinoma over time [28,31]. MCF10AT1 cells
were transduced with pLenti-GRM1, and the pooled cell
population was implanted into the flanks of athymic nude mice.
We chose to use pooled cell populations, rather than picking a
series of individual clones, because we were screening for an effect
and did not wish to use more animals than necessary to do so.
Wild type (Figure 9A) and LacZ-transduced MCF10AT1
(Figure 9B) formed predominantly hyperplastic lesions exhibiting
Figure 6. mGluR1 activity regulates cell proliferation. A. Proliferation. mGluR1 overexpression significantly increased proliferation of
MCF10AT1 cells compared to the control as measured by MTT assay. For MTT assay, 16104 cells were plated and cell proliferation was analyzed on
day 3. B. Cell counts. Cell counting by Coulter counter also show that mGluR1 overexpression significantly increased proliferation of MCF10AT1 cells
compared to the control LACZ cells. C. Pharmacological inhibition of mGluR1 inhibits TNBC cell proliferation. Proliferation, as measured by
cell counts of MCF10CA1d cells was significantly inhibited by glutamatergic signaling inhibitor, BAY. D and E. Effect of silencing mGluR1.
Silencing GRM1 significantly decreased cell growth compared to the NS vector control in GRM1- MCF10AT1 cells (D) and in malignant MCF10CA1d
cells (E). For B, C, D, and E, growth assays, 56104 cells were plated in 6-well tissue culture plates and cell numbers counted by Coulter counter on day
3 for B, D, E growth assays and for C growth assay cells were counted on day 6 after plating. Results are recorded as mean 6 SEM of replicate
experiments, where *p,0.05 compared to control. Legend: NS = pLenti vector containing nonsilencing control; shGRM1=pLenti vector containing
shRNA against GRM1; LacZ=pLenti-LacZ; GRM1=pLenti-GRM1.
doi:10.1371/journal.pone.0081126.g006
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complex patterns of intraductal epithelial proliferations with
papillary enfolding and cribiform areas, which is consistent with
the original description of xenografts formed by premalignant
MCF10AT1 cells [32]. Only 27% and 22% of xenografts derived
from LacZ and wild-type controls, respectively, developed foci of
invasive carcinoma, rates well within the range of expected results
for wild type MCF10AT1 cells and not statistically significantly
different from each other (p.0.10, chi-squared). In comparison,
xenografts derived from the MCF10AT1 pooled cell population
overexpressing mGluR1 developed multiple foci of invasive
carcinoma in over 90% of lesions, some of which grew to take
over the entire lesion (Figure 9, C and D). We note that this
result is the more striking in light of our previous report that
activated Ras and Neu showed an additive effect in transformation
of MCF10A cells by in vitro criteria xenografts but Ras- and Neu-
transduced MCF10AT1 cells were not tumorigenic in nude mice
[46]. We have also observed that MCF10AT1 transfected with c-
erb2 formed hyperplastic lesions in xenografts with no augmented
ability to progress to carcinoma (Miller, unpublished). Our results
suggest that mGluR1 can contribute to the transformation of
hyperplasic breast epithelium and that its expression contributes to
the progression of TNBC.
Conclusions
Glutamatergic signaling is now known to be important as a
regulator of phenotype and proliferation of cells outside the CNS
[15–18,47]. Here we report that mGluR1 can also transform
hyperplastic mammary epithelium. Our results are particularly
relevant to TNBC, for which the identification of a new molecular
target would represent a major advance. When mGluR1 was
expressed in the parental MCF10A cell line, we did not observe
increased proliferation, migration, invasion, or anchorage-inde-
pendent growth. In marked contrast, when mGluR1 was
ectopically expressed in c-Ha-ras-transformed MCF10AT1 cells
we observed characteristics of a malignant phenotype. These
results suggest that, although mGluR1 is clearly oncogenic in
melanoma [48], in breast cancer its function appears to be more
complex. Consistent with the concept that multiple genetic
changes are usually required to transform a normal cell to a
malignant phenotype, mGluR1 appears to function in the
background of genetic changes that ‘‘prime’’ the cell (in
MCF10AT1, c-Ha-ras) to respond to the activity of mGluR1 by
transformation and there appears to be a dose requirement, given
that MCF10AT1 cells already express more mGluR1 than
MCF10A. How mGluR1 and c-Ha-ras cooperate to result in
malignant transformation in TNBC remains to be elucidated.
Our results also have implications for therapy. Currently, unlike
the case for ER(+) or HER2(+) breast cancer, there are no
validated molecular targets in TNBC, leaving cytotoxic chemo-
therapy, with all its attendant toxicity, as the only effective systemic
therapy. Our results build on our previous results [9] demonstrat-
ing that blocking glutamatergic signaling has significant antitumor
effects against TNBC by asking converse question, namely what
happens when mGluR1 expression increases in nontransformed
Figure 7. mGluR1 regulates TNBC migration and invasion. MCF10AT1 or MCF10CA1d cells were transduced either with pLenti-GRM1, pLenti-
LacZ, shGRM1, or NS control. 2.56105 cells were plated on polycarbonate containing cell inserts and migration or invasion towards chemoattractant
(10% serum) was measured after 24 hours. For invasion assays, polycarbonate membranes were coated with reconstituted basement membrane. A.
mGluR1 stimulates MCF10AT1 migration. GRM1 overexpression in MCF10AT1 cells significantly increased migration of the cells compared to
the control LacZ cells, which was reversed (B) by silencing with shGRM1. C. MCF10AT1 invasion. GRM1 overexpression significantly stimulated the
invasion of MCF10AT1 cells through polycarbonate membranes coated with reconstituted basement membrane. D. MCF10CA1d invasion.
shGRM1 knockdown inhibited the invasion of malignant MCF10CA1d cells compared to the NS transduced cells. Results are recorded as the mean 6
SEM of three experiments, where *p,0.05 compared to control. Legend: NS =nonsilencing control; shGRM1= shRNA against GRM1; LacZ=pLenti-
LacZ; GRM1=pLenti-GRM1.
doi:10.1371/journal.pone.0081126.g007
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and premalignant mammary epithelium. We recently reported
that riluzole (RilutekH), an FDA-approved inhibitor of glutama-
tergic signaling with an extremely favorable safety and side effect
profile currently used to treat patients with ALS [49,50], can
inhibit the growth of TNBC xenografts in mice [9]. One potential
problem in translating our results to the clinic is that, although
BAY is a specific mGluR1 inhibitor, riluzole, the only current
inhibitor of glutamatergic signaling in clinical use, is not. This
makes comparisons between antitumor effects due to Riluzole or
BAY difficult, as riluzole can also inhibit sodium channels [51] and
calcium channels [52] as well as PKC activity. It is possible,
however, that the less specific inhibitor could end up being the
more effective treatment, particularly given its excellent safety and
toxicity profile.
Our current results constitute an important observation that
argues for a significant role for mGluR1 in TNBC progression and
extends our recent results [9] by beginning to elucidate at what
point in breast cancer progression mGluR1 functions. We envision
repurposing an inhibitor of glutamatergic like riluzole as a
treatment for TNBC that is oral, safe, and relatively nontoxic or
developing a more highly specific inhibitor of mGluR1, such as
BAY, that serves a similar purpose. It might also be possible to
combine targeted agents directed at mGluR1 and c-Ha-ras
signaling in order to produce synergistic toxicity in mGluR1-
expressing TNBC.
To our knowledge, this is the first report implicating mGluR1 as
a potential oncogene and therapeutic target in breast cancer. It
will be important going forward to identify the subtypes of breast
cancer that express the most mGluR1 in order to determine the
best clinical situations in which inhibition of glutamatergic
signaling will have maximal effects and whether somatic mutations
in this gene contribute to the development of TNBC, given that
such mutations exist in other cancers and TNBC [22,53]. Future
efforts will also focus on isolating individual mGluR1-overexpress-
ing clones and using them to elucidate how mGluR1 interacts with
other oncogenes, such as c-Ha-ras to transform basal epithelium
and how to target glutamatergic signaling, either alone or in
concert with other targeted therapies, more effectively in the
treatment of breast cancer.
Figure 8. mGluR1 facilitates anchorage-independent growth. A and B. MCF10AT1 cells. Cells were transduced with either with pLenti-
GRM1, pLenti-LacZ, shGRM1, or NS control vector and stably selected before plating in soft agar. GRM1 overexpression significantly increased number
of colonies on soft agar compared to the control LacZ cells (A), an effect reversed by shGRM1 (B). C. MCF10CA1d cells. Silencing GRM1 significantly
decreased colony formation compared to the non-silencing (NS) vector control in MCF10CA1d cells. Finally, colony formation is inhibited by BAY in
both MCF10DCIS.com cells (D) and MCF10CA1d cells (E). For all assays 16105 cells were suspended in 0.4% agarose and colonies formed on the soft
agar were counted after three weeks on Gel Count machine. Results are recorded as the mean 6 SEM of three experiments, where *p,0.05
compared to control. F. Live cell imaging of 4 day MAME cultures of MCF10AT1-LacZ and MCF10AT1-GRM1 cells illustrate increases in
proliferative and invasive phenotype in cells expressing GRM1. 15,000 cells were seeded per coverslip on reconstituted basement
membrane. Differential Interference Contrast images from 16 contiguous fields were obtained with a Zeiss LSM-510 META confocal microscope. Tiled
images allow one to see the relative sizes of the structures formed over a 4-day period. Bar, 100 mm. Legend: LacZ=pLenti-LacZ; GRM1=pLenti-
GRM1.
doi:10.1371/journal.pone.0081126.g008
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